Sanofi (NASDAQ:SNY) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC raised its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 4.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,874,193 shares of the company's stock after acquiring an additional 114,133 shares during the quarter. Natixis Advisors LLC owned approximately 0.11% of Sanofi worth $165,640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Northwest Investment Counselors LLC bought a new position in Sanofi during the third quarter valued at approximately $29,000. POM Investment Strategies LLC bought a new position in shares of Sanofi in the second quarter worth about $25,000. Concord Wealth Partners raised its stake in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company's stock valued at $34,000 after acquiring an additional 363 shares in the last quarter. Arrow Financial Corp purchased a new position in shares of Sanofi during the second quarter valued at $35,000. Finally, Fortitude Family Office LLC raised its stake in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company's stock worth $43,000 after buying an additional 659 shares in the last quarter. Institutional investors own 10.04% of the company's stock.

Sanofi Trading Up 0.3 %

NASDAQ:SNY traded up $0.15 on Friday, hitting $47.97. The stock had a trading volume of 3,651,145 shares, compared to its average volume of 2,038,351. The stock has a market cap of $121.74 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 1.26 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a fifty day moving average price of $54.65 and a two-hundred day moving average price of $52.19. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the firm posted $2.55 earnings per share. Sanofi's revenue was up 12.3% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.27 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on SNY shares. Argus raised their price target on Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.